|
1
|
Bonavia R, Inda MM, Cavenee WK and Furnari
FB: Heterogeneity maintenance in glioblastoma: A social network.
Cancer Res. 71:4055–4060. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Persano L, Rampazzo E, Basso G and Viola
G: Glioblastoma cancer stem cells: Role of the microenvironment and
therapeutic targeting. Biochem Pharmacol. 85:612–622. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ostrom QT, Gittleman H, Farah P, Ondracek
A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C and Barnholtz-Sloan JS:
CBTRUS statistical report: Primary brain and central nervous system
tumors diagnosed in the united states in 2006–2010. Neuro-Oncol. 15
Suppl 2:ii1–ii56. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Furnari FB, Fenton T, Bachoo RM, Mukasa A,
Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, et al:
Malignant astrocytic glioma: Genetics, biology, and paths to
treatment. Genes Dev. 21:2683–2710. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Malzkorn B and Reifenberger G: Practical
implications of integrated glioma classification according to the
World Health Organization classification of tumors of the central
nervous system 2016. Curr Opin Oncol. 28:494–501. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Colman H and Aldape K: Molecular
predictors in gliobla=stoma: Toward personalized therapy. Arch
Neurol. 65:877–883. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Verhaak RG, Hoadley KA, Purdom E, Wang V,
Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al:
Integrated genomic analysis identifies clinically relevant subtypes
of glioblastoma characterized by abnormalities in PDGFRA, IDH1,
EGFR, and NF1. Cancer Cell. 17:98–110. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Toki S, Kagaya S, Shinohara M, Matsumoto
T, Takahata Y, Saito H and Matsumoto K: Genome-wide gene expression
analysis of the human intestinal epithelial cells after stimulation
with lactic acid bacteria. J Allerg Clin Immunol. 117:S1532006.
View Article : Google Scholar
|
|
9
|
Hazan RB, Qiao R, Keren R, Badano I and
Suyama K: Cadherin switch in tumor progression. Ann N Y Acad Sci.
1014:155–163. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wheelock MJ, Shintani Y, Maeda M, Fukumoto
Y and Johnson KR: Cadherin switching. J Cell Sci. 121:727–735.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Anastasiadis PZ: p120-ctn: A nexus for
contextual signaling via Rho GTPases. Biochim Biophys Acta.
1773:34–46. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gumbiner BM: Cell adhesion: The molecular
basis of tissue architecture and morphogenesis. Cell. 84:345–357.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nelson WJ and Nusse R: Convergence of Wnt,
beta-catenin, and cadherin pathways. Science. 303:1483–1487. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu KV, Chang JP, Parachoniak CA, Pandika
MM, Aghi MK, Meyronet D, Isachenko N, Fouse SD, Phillips JJ,
Cheresh DA, et al: VEGF inhibits tumor cell invasion and
mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell.
22:21–35. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Newcomb EW, Cohen H, Lee SR, Bhalla SK,
Bloom J, Hayes RL and Miller DC: Survival of patients with
glioblastoma multiforme is not influenced by altered expression of
p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol. 8:655–667. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sacco JJ, Coulson JM, Clague MJ and Urbé
S: Emerging roles of deubiquitinases in cancer-associated pathways.
IUBMB Life. 62:140–157. 2010.PubMed/NCBI
|
|
17
|
Stevenson LF, Sparks A, Allende-Vega N,
Xirodimas DP, Lane DP and Saville MK: The deubiquitinating enzyme
USP2a regulates the p53 pathway by targeting Mdm2. EMBO J.
26:976–986. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
van der Horst A, de Vries-Smits AM,
Brenkman AB, van Triest MH, van den Broek N, Colland F, Maurice MM
and Burgering BM: FOXO4 transcriptional activity is regulated by
monoubiquitination and USP7/HAUSP. Nat Cell Biol. 8:1064–1073.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Colland F, Formstecher E, Jacq X, Reverdy
C, Planquette C, Conrath S, Trouplin V, Bianchi J, Aushev VN,
Camonis J, et al: Small-molecule inhibitor of USP7/HAUSP ubiquitin
protease stabilizes and activates p53 in cells. Mol Cancer Ther.
8:2286–2295. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Allende-Vega N, Sparks A, Lane DP and
Saville MK: MdmX is a substrate for the deubiquitinating enzyme
USP2a. Oncogene. 29:432–441. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fraile JM, Quesada V, Rodríguez D, Freije
JM and López-Otín C: Deubiquitinases in cancer: New functions and
therapeutic options. Oncogene. 31:2373–2388. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu M, Takanashi M, Oikawa K, Tanaka M,
Nishi H, Isaka K, Kudo M and Kuroda M: USP15 plays an essential
role for caspase-3 activation during Paclitaxel-induced apoptosis.
Biochem Biophys Res Commun. 388:366–371. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Inui M, Manfrin A, Mamidi A, Martello G,
Morsut L, Soligo S, Enzo E, Moro S, Polo S, Dupont S, et al: USP15
is a deubiquitylating enzyme for receptor-activated SMADs. Nat Cell
Biol. 13:1368–1375. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Eichhorn PJ, Rodón L, Gonzàlez-Juncà A,
Dirac A, Gili M, Martínez-Sáez E, Aura C, Barba I, Peg V, Prat A,
et al: USP15 stabilizes TGF-β receptor I and promotes oncogenesis
through the activation of TGF-β signaling in glioblastoma. Nat Med.
18:429–435. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guo Z, Li G, Bian E, Ma CC, Wan J and Zhao
B: TGF-β-mediated repression of MST1 by DNMT1 promotes glioma
malignancy. Biomed Pharmacother. 94:774–780. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao Y, Wang J, Yang J and Miao J:
Synergistic antitumor effect of ING4/PTEN double tumor suppressors
mediated by adenovirus modified with RGD on glioma. J Neurosurg
Sci. Apr 12–2017.(Epub ahead of print).
|
|
27
|
Yang W, Xia Y, Ji H, Zheng Y, Liang J,
Huang W, Gao X, Aldape K and Lu Z: Nuclear PKM2 regulates β-catenin
transactivation upon EGFR activation. Nature. 480:118–122. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gupta GP and Massagué J: Cancer
metastasis: Building a framework. Cell. 127:679–695. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Paw I, Carpenter RC, Watabe K, Debinski W
and Lo HW: Mechanisms regulating glioma invasion. Cancer Lett.
362:1–7. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Onder TT, Gupta PB, Mani SA, Yang J,
Lander ES and Weinberg RA: Loss of E-cadherin promotes metastasis
via multiple downstream transcriptional pathways. Cancer Res.
68:3645–3654. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Takeichi M: Morphogenetic roles of classic
cadherins. Curr Opin Cell Biol. 7:619–627. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Savagner P: The epithelial-mesenchymal
transition (EMT) phenomenon. Ann Oncol. 21 Suppl 7:vii89–vii92.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hanahan D and Weinberg R: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huang X, Langelotz C, Hetfeld-Pechoc BK,
Schwenk W and Dubiel W: The COP9 signalosome mediates beta-catenin
degradation by deneddylation and blocks adenomatous polyposis coli
destruction via USP15. J Mol Biol. 391:691–702. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Schweitzer K, Bozko PM, Dubiel W and
Naumann M: CSN controls NF-kappaB by deubiquitinylation of
IkappaBalpha. EMBO J. 26:1532–1541. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Graner E, Tang D, Rossi S, Baron A, Migita
T, Weinstein LJ, Lechpammer M, Huesken D, Zimmermann J, Signoretti
S and Loda M: The isopeptidase USP2a regulates the stability of
fatty acid synthase in prostate cancer. Cancer Cell. 5:253–261.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Oh KH, Yang SW, Park JM, Seol JH, Iemura
S, Natsume T, Murata S, Tanaka K, Jeon YJ and Chung CH: Control of
AIF-mediated cell death by antagonistic functions of CHIP ubiquitin
E3 ligase and USP2 deubiquitinating enzyme. Cell Death Differ.
18:1326–1336. 2011. View Article : Google Scholar : PubMed/NCBI
|
